Rituximab in idiopathic membranous nephropathy

Area of Science:

• Nephrology
• Immunology
• Autoimmune Diseases

Background:

• Idiopathic membranous nephropathy (IMN) is a leading cause of nephrotic syndrome in adults.
• Current treatments for IMN have variable efficacy and potential side effects.
• Selective B-cell depletion with rituximab is a potential therapeutic strategy for IMN.

Purpose of the Study:

• To evaluate the efficacy and safety of rituximab in a large cohort of IMN patients with persistent nephrotic syndrome.
• To assess remission rates, time to remission, and impact on renal function.
• To identify predictors of proteinuria reduction and renal function decline.

Main Methods:

• A consecutive series of 100 IMN patients with persistent nephrotic syndrome were treated with rituximab.
• Remission was defined as proteinuria <0.3 g/24h (complete) or <3 g/24h (partial) with >50% reduction from baseline.
• Median follow-up was 29 months; renal function (GFR) and proteinuria were monitored.

Main Results:

• 65 patients achieved complete or partial remission, with a median time to remission of 7.1 months.
• All patients with at least 4 years of follow-up achieved remission.
• Significant improvements in GFR, serum albumin, and albumin fractional clearance were observed in responders.
• Proteinuria at baseline and follow-up duration predicted proteinuria decline; proteinuria reduction correlated with slower GFR decline.

Conclusions:

• Rituximab is an effective treatment for achieving remission in high-risk IMN patients.
• Rituximab stabilizes or improves renal function in IMN patients.
• The treatment demonstrated a favorable safety profile with no serious adverse events.